Skip to main content

ERRATUM article

Front. Pediatr., 05 November 2024
Sec. Pediatric Urology
Volume 12 - 2024 | https://doi.org/10.3389/fped.2024.1514803
This article is part of the Research Topic Reviews in Pediatric Urology 2024 View all 12 articles

Erratum: X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteriscs of a single-center pediatric cohort in North America before and after burosumab

This article is an erratum on:

  1. X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab

    1. Read original article
\r\nFrontiers Production Office\r\nFrontiers Production Office
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on

X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab

By Paloian NJ, Boyke-Lohmann LR and Steiner RD (2024). Front. Pediatr. 12: 1430921. doi: 10.3389/fped.2024.1430921

Due to an error, the funder for the article processing charge “Dr. Penniston (Department of Urology, University of Wisconsin-Madison)” was erroneously omitted.

The conflict of interest statement was incorrectly reported as “RS reports consulting fees from Leadiant, Mirum, PTC, and Travere. He is a shareholder of Exact Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest”.

The correct conflict of interest statement is “RS reports consulting fees from Leadiant, Mirum, PTC, and Travere. He is a shareholder of Exact Sciences. NJ, LB-L, RS, and the funder, Dr. Penniston, are all employed by the University of Wisconsin”.

The publisher apologizes for this mistake. The original version of this article has been updated.

Keywords: XLH, rickets, hypophosphatemia, nephrocalcinosis, burosumab

Citation: Frontiers Production Office (2024) Erratum: X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteriscs of a single-center pediatric cohort in North America before and after burosumab. Front. Pediatr. 12:1514803. doi: 10.3389/fped.2024.1514803

Received: 21 October 2024; Accepted: 25 October 2024;
Published: 5 November 2024.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright: © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.